Defining Treatment Goals and PD-L1–Driven Strategies in Metastatic NSCLC: Applying Insights From CheckMate-9LA

In Defining Treatment Goals and PD-L1–Driven Strategies in Metastatic NSCLC: Applying Insights From CheckMate-9LA, our panel/experts delve(s) into the following critical questions:

What are your main treatment goals for patients with metastatic NSCLC?

How does PD-L1 status affect your management decisions in patients with metastatic NSCLC?

What are your main takeaways from the CheckMate-9LA clinical trial?

Led by Dr. Dietrich, Drs. Niu, Nadler, and Dowlati discussed the primary treatment goals for patients with metastatic NSCLC by focusing on prolonging overall survival, controlling disease-related symptoms, maintaining or improving quality of life, and minimizing treatment-related toxicity. Achieving these goals requires a personalized approach that incorporates tumor histology, molecular alterations, performance status, comorbidities, and patient preferences. PD-L1 expression remains a critical biomarker in metastatic NSCLC, guiding the selection and sequencing of immunotherapy, either as monotherapy in high expressors or in combination with chemotherapy for broader populations. Even patients with low or negative PD-L1 can benefit from chemoimmunotherapy combinations, highlighting the need for an integrated treatment strategy rather than reliance on a single biomarker.

The phase 3 CheckMate 9LA trial demonstrated that combining nivolumab and ipilimumab with a limited course of chemotherapy improved overall survival compared with chemotherapy alone, with a safety profile consistent with known immune-related adverse events. Importantly, the trial showed efficacy across PD-L1 subgroups, supporting broader use of dual immune checkpoint inhibition in appropriately selected patients. These results inform clinical practice by emphasizing the value of upfront combination strategies that balance rapid disease control with durable immune-mediated responses. Overall, management decisions are driven by a combination of biomarker-guided therapy, patient-specific goals, and evidence from trials such as CheckMate 9LA to optimize outcomes in metastatic NSCLC.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, Dual Immunotherapy Strategies in Metastatic NSCLC: Evidence, Safety, and Clinical Decision-Making, further explores management decisions for patietns with lung cancer.